“We look forward to reporting clinical data from our Phase 1/2 DELIVER trial of DYNE-251 anticipated in the second half of 2023, as this is an important milestone in our efforts to develop new exon skipping therapies for people living with this devastating disease.”ĭMD is a rare disease caused by mutations in the gene that encodes for dystrophin, a protein critical for the normal function of muscle cells.
The poster being presented at World Muscle features foundational preclinical data underpinning the clinical development program for DYNE-251 and the first in vitro data for a FORCE conjugate targeting exon 53,” said Oxana Beskrovnaya, Ph.D., chief scientific officer of Dyne. Beyond DYNE-251, our product candidate targeting exon 51, we are leveraging the modularity of the FORCE platform to rapidly identify candidates for other exons, including 53, 45 and 44.
“We are excited to present data which highlight the potential of our FORCE™ platform in building a global DMD franchise of exon skipping therapies. The data are featured in a poster at the 27 th International Hybrid Annual Congress of the World Muscle Society taking place in Halifax, Nova Scotia, Canada from October 11-15, 2022. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the presentation of preclinical data from its Duchenne muscular dystrophy (DMD) programs for the treatment of individuals with DMD mutations amenable to skipping exons 51 or 53. WALTHAM, MA, USA I OctoI Dyne Therapeutics, Inc. First Presentation of In Vitro Data for FORCE™ Platform Conjugate Targeting Exon 53. Poster Highlights In Vivo Data for DYNE-251, Now Being Evaluated in Phase 1/2 DELIVER Clinical Trial in Patients Amenable to Exon 51 Skipping.
0 kommentar(er)
